Immunogenicity affects candidate success


Lonza’s proprietary Epibase® in silico platform is a patented T cell epitope screening tool for the identification of potential epitopes in a biotherapeutic protein. The tool is driven by sequence information, structural bioinformatics, and experimental data. The Epibase® in silico tool uses structural characteristics of the HLA receptor along with experimentally determined binding affinities to predict potential peptide/HLA binding, a condition necessary for T cell activation.

The Epibase® in silico tool supports lead candidate selection, ranking, optimization and design for the development of biotherapeutic proteins with reduced immunogenicity risk.

Help Increase Chance of Clinical Success

  • Global population coverage, greater than 99% coverage, including 85 HLA Class II allotypes
  • Analysis includes binding affinity, promiscuity and frequency of allotypes
  • High accuracy of prediction based on in vitro correlations
  • Reduce immune response with in silico-guided engineering of epitope sequences
  • Can link in silico results with Epibase® in vitro assays for confirmation of promising candidates

Save Time and Money in Development

  • Lonza's scientific experts perform the work, analyze results and provide consultation on data interpretation
  • Rapidly assess biotherapeutic proteins with a high throughput process
  • Streamline candidate selection using in silico screening to select lower risk candidates before proceeding to in vitro screening
  • Focus R&D resources on a smaller number of protein targets with the greatest chance of success early in development 

Download poster on Immunogenicity assessment capabilities

Computational Approaches for Prediction of Developablity Properties and Risk Mitigation of Biotherapeutics